Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosseti Volga reported for 3 months of 2023 by RAS

4/28/23 MRKV

Samolet reported for 2022 by IFRS

4/28/23 SMLT

Gilead Sciences announced a quarterly dividend

4/28/23 GILD

Shareholders of Moscow Exchange could not make a decision on dividends

4/28/23 MOEX

Mother and Child summed up the results of work in the 1st quarter

4/28/23 MDMG

VKontakte's first NFT collection sold out in 30 minutes

4/28/23 VKCO

First Solar reported for 3 months of 2023

4/28/23 FSLR

Abbott bought Cardiovascular Systems

4/28/23 CSII

Abbott bought Cardiovascular Systems

4/28/23 ABT

Mondelēz International reported for 3 months of 2023

4/28/23 MDLZ